This has led to the suggestion that in prion disease, where the central role of PrP in disease is incontrovertible56, the lowering of CSF PrP — a target engagement biomarker only — could serve as a primary endpoint in trials of at-risk individuals21. This evidence concerns the gene PRNP and prion disease.